[Correspondence] Global health equity and diagnosis of sepsis in low-income and middle-income countries

We read with great interest the Comment by Peter Hyland and colleagues in The Lancet Microbe on the crucial issue of the unaffordable cost of blood cultures for individuals in low-income and middle-income countries (LMICs).1 Further to their analysis, we would like to add that most patients in LMICs cannot afford the cost of US$5–7 per blood culture bottle or the cost of antimicrobial susceptibility testing, which for automated systems can be an additional $15–20 per blood culture sample.1